MedTrace Logo

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

NCT00005052 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-02-09

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than observation alone for melanoma.

PURPOSE: This randomized phase III trial is studying vaccine therapy to see how well it works compared to observation alone in treating patients with primary stage II melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

GM2-KLH vaccine

BIOLOGICAL

QS21

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Alexander M. M. Eggermont, MD, PhD · Daniel Den Hoed Cancer Center at Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31

Countries

  • Australia
  • Belgium
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Serbia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005052 on ClinicalTrials.gov